2025-12-19 - Analysis Report
Okay, here's a breakdown of the JNJ stock data, followed by analysis and a comprehensive summary.

**1. Return Rate Comparison**

*   **Ticker:** JNJ (Johnson & Johnson)
*   **Company Overview:** Johnson & Johnson is a global healthcare company engaged in the research and development, manufacture, and sale of a broad range of products in the healthcare field.
*   **JNJ Cumulative Return:** 60.54%
*   **VOO (S&P 500) Cumulative Return:** 99.09%
*   **Divergence:**
    *   Current: -38.5
    *   Max: 16.6
    *   Min: -65.5
    *   Relative Divergence: 32.9

**Analysis of Return Rate:**

JNJ has significantly underperformed the S&P 500 (VOO) in terms of cumulative return. The current divergence of -38.5% indicates a substantial gap in performance. The relative divergence of 32.9 suggests that JNJ's current performance relative to VOO is in the lower end of its historical divergence range.

**Alpha, Beta Analysis:**

| Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
|------------|--------|-------|--------|------|--------|
| 2015-2017  | 26.0%  | 66.8% | -2.0%  | -0.1 | 336.6  |
| 2016-2018  | 14.0%  | 10.7% | -1.0%  | 0.1  | 310.9  |
| 2017-2019  | 20.0%  | 71.5% | -2.0%  | 0.4  | 351.4  |
| 2018-2020  | 19.0%  | 79.2% | -4.0%  | 0.4  | 379.2  |
| 2019-2021  | 33.0%  | 79.2% | -14.0% | 0.5  | 412.2  |
| 2020-2022  | 8.0%   | 79.6% | 9.0%   | 0.4  | 425.6  |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3  | 377.6  |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3  | 348.4  |
| 2023-2025  | 32.0%  | 79.6% | -32.0% | 0.1  | 501.9  |

**Analysis of Alpha, Beta:**

*   **Alpha:** JNJ has consistently exhibited negative alpha, particularly in more recent periods. This indicates that it has underperformed relative to its expected return based on its beta and the market return. While it showed 9% in 2020-2022, the alpha score got worse recently, from -20% in 2021-2023 to -53% in 2022-2024, and then improved to -32% in 2023-2025.
*   **Beta:** The beta values are generally low (around 0.1-0.5), indicating that JNJ's price movements are less volatile than the overall market. This suggests it is a relatively stable stock.
*   **CAGR:** Fluctuating CAGR, but got better recently, from -32% in 2022-2024 to 32% in 2023-2025.
*   **MDD:** High MDD value indicates more loss in the provided period.

**2. Recent Stock Price Fluctuations**

*   **Closing Price:** 208.31
*   **Previous Close:** 210.33
*   **Change:** -0.96
*   **5-day SMA:** 210.738
*   **20-day SMA:** 206.296
*   **60-day SMA:** 195.3537

**Analysis of Price Fluctuations:**

The closing price is slightly below the previous close, indicating a minor recent downturn. The 5-day SMA is above the current price, but the 20-day SMA is below the current price and the 60-day SMA is even further below. This suggests that JNJ's price has been increasing recently, but this upward trend could potentially face resistance if it continues.

**3. RSI, PPO, and Divergence Indicators**

*   **Market Risk Indicator (MRI):** 0.7 (Medium Investment)
*   **RSI:** 52.13
*   **PPO:** -0.0426
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80) (Cash Ratio: 0% on 2025-12-03)
*   **Recent (20 days) relative divergence change:** 10.2 (+) (Short-term increase)
*   **Expected Return (%):** -48.4 (Expected underperformance compared to S&P 500)

**Analysis of Indicators:**

*   **MRI:** A value of 0.7 indicates a medium level of investment risk.
*   **RSI:** An RSI of 52.13 suggests that the stock is neither overbought nor oversold.
*   **PPO:** A slightly negative PPO indicates that the short-term moving average is marginally below the long-term moving average.
*   **Hybrid Signal:** This suggests a moderately bullish outlook, with a recommendation to buy.
*   **Divergence Change:** The recent increase in relative divergence suggests a short-term upward trend relative to its historical performance.
*   **Expected Return:** A negative expected return implies that, based on current data, JNJ is projected to underperform the S&P 500 over the long term.

**4. Recent News & Significant Events:**

*   **FDA News & Stock Movement:** News regarding the FDA impacting JNJ, potentially driving recent price changes. (ts2.tech)
*   **Valuation Perspectives:** Articles analyzing JNJ's valuation after recent price increases. (Yahoo Finance)
*   **Reason for Surge:**  Motley Fool article explaining a reason for a surge in share price.
*   **Shares Sold by Firm:** MarketBeat reports a sale of JNJ shares by an investment firm.
*   **Stock Forecast:** EBC Financial Group provides stock forecast, including key levels and resistance levels.
*   **Valuation Premium Justified:** Seeking Alpha article argues a valuation premium for JNJ is justified by growth and mix premiumization.

**Analysis of News:**

Recent news is mixed. While some articles focus on positive valuation justifications and drivers of price increases, there's also news of a firm selling shares. The mention of FDA news is important, as regulatory decisions often significantly impact pharmaceutical stocks.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 2.16)
*   **Target Price:** Avg: 208.17 / High: 240.00 / Low: 155.00
*   **Recent Rating Changes:**  (No specific changes provided)

**Analysis of Analyst Opinions:**

The analyst consensus is generally positive (Buy), suggesting that analysts believe the stock will perform well. The average target price is close to the current price, with a high target price suggesting potential upside and a low target price highlighting potential downside risk. Without the direction of the rating changes, it is hard to tell if the analyst consensus are getting more or less optimistic.

**5. Recent Earnings Analysis:**

| 날짜       | EPS  | 매출       |
|------------|------|------------|
| 2025-10-22 | 2.14 | 23.99 B$   |
| 2025-07-24 | 2.3  | 23.74 B$   |
| 2025-04-23 | 4.57 | 21.89 B$   |
| 2024-10-23 | 1.12 | 22.47 B$   |
| 2025-10-22 | 1.12 | 22.47 B$   |

**Analysis of Earnings:**

*   **EPS:** EPS has fluctuated significantly, with a high of 4.57 and lows of 1.12.
*   **Revenue:** Revenue shows an upward trend generally.
*   **Duplicate date (2025-10-22):** Please double check data source.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $23.99B  | 69.56%        |
| 2025-06-30   | $23.74B  | 67.87%        |
| 2025-03-31   | $21.89B  | 66.40%        |
| 2024-12-31   | $22.52B  | 68.35%        |
| 2024-09-30   | $22.47B  | 69.01%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE   |
|--------------|----------|-------|
| 2025-09-30   | $79.28B  | 6.50% |
| 2025-06-30   | $78.47B  | 7.06% |
| 2025-03-31   | $78.11B  | 14.08%|
| 2024-12-31   | $71.49B  | 4.80% |
| 2024-09-30   | $70.16B  | 3.84% |

**Analysis of Financial Information:**

*   **Revenue:** Consistent revenue growth, with the latest quarter showing the highest revenue in the provided data.
*   **Profit Margin:** Relatively stable profit margins, consistently high.
*   **Equity:** Increasing equity over the period, indicating strong financial health.
*   **ROE:** ROE is volatile. High in 2025-03-31 (14.08%), which is not sustainable.

**7. Comprehensive Analysis (Summary)**

Johnson & Johnson (JNJ) presents a mixed picture. Here's a summary of key findings:

*   **Underperformance vs. S&P 500:** JNJ has significantly underperformed the S&P 500 in recent years, as reflected in the negative divergence.
*   **Low Volatility:** JNJ is a relatively stable stock with low beta.
*   **Mixed Technical Indicators:** RSI is neutral, and PPO slightly negative. Short-term divergence is positive.
*   **Positive Analyst Sentiment:**  The analyst consensus is "Buy" with target prices clustered around the current price.
*   **Recent News is Mixed:** Positive and negative headlines surrounding the stock, indicating some uncertainty or volatility.
*   **Solid Financials:** Revenue and profit margins are strong and stable.
*   **Earnings Volatility:** EPS fluctuates significantly.
*   **Expected Return:** Negative. This should be taken as a major caution and should be confirmed through additional analysis.

**Overall Recommendation:**

Based on the available information, a cautious approach is warranted. The underperformance compared to the S&P 500, negative expected return, and fluctuating EPS are concerns. While analyst sentiment is positive and the financials are solid, investors should carefully consider the risks before investing. The recent short-term upward trend could present a buying opportunity, but further research and monitoring of news events (especially those related to regulatory decisions) are essential.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.